Synopsis: FTC-approved $250 million deal is set to support US growth, add new complex medicines, improve manufacturing capacity, and help increase earnings through better scale and efficiency over time.
The article outlines the importance of the deal for this pharma company, which operates in over 150 countries, specializing in generic drugs, active pharmaceutical ingredients, and injectables across therapeutic areas like antibiotics, CVS, CNS, and anti-retrovirals
With a market capitalization of Rs 87,817 crore, Aurobindo Pharma Ltd’s shares currently trade at Rs 1,512 per share, up 1.32 percent from the previous day’s close. The company’s share gave a return of 60.5 percent over the last five years.
Key Highlights of the Deal
Aurobindo Pharma’s wholly owned subsidiary, Aurobindo Pharma USA, has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC for $250 million. The transaction is expected to be completed before the end of June 2026 and will strengthen the company’s position in the U.S. generic pharmaceutical market through an expanded product portfolio.
The acquisition will also add Lannett’s manufacturing facility in Seymour, Indiana, which has the capacity to produce nearly 4 billion doses annually. Besides enhancing Aurobindo’s domestic manufacturing footprint in the U.S., the deal is expected to be immediately earnings-accretive and to provide long-term benefits through operational synergies, cost efficiencies, and a stronger pipeline of complex generic products.
How the Lannett Deal Can Benefit Aurobindo Pharma?
Accelerates US Revenue Growth: The Lannett deal can help Aurobindo Pharma grow its US business at a faster pace. It supports a path toward nearly USD 2 billion in US sales in FY27, compared to around USD 1.6 billion in FY26, improving overall scale in a key market.
Expands Complex Generics Portfolio: Lannett adds complex generic products to Aurobindo Pharma’s portfolio. These products usually have higher entry barriers and better pricing strength, which can help the company improve its mix toward more specialised and relatively higher-margin opportunities in the US generics space.
Improves Manufacturing Capacity Utilisation: The acquisition also brings additional manufacturing capacity, which can be used more efficiently. Better utilisation typically improves operating leverage, where fixed costs are spread over higher output, supporting stable margins and better cost absorption over time.
Supports Long-Term Earnings Growth Drivers: The deal includes potential upside from products like the planned generic Advair inhaler launch in the US. Along with expected cost and operational synergies, this can support steady earnings improvement and strengthen long-term profitability for Aurobindo Pharma.
HSBC maintained a Buy rating on Aurobindo Pharma with a target price of Rs 1,580, citing benefits from the Lannett acquisition, potential upside from the Advair launch, and improving growth visibility in the US market.
Management Commentary: Swami S. Iyer, Chief Executive Officer of Aurobindo Pharma USA, said the acquisition is a strong strategic and financial move that supports faster revenue growth and improves US manufacturing capabilities. He added that it strengthens the company’s position in complex non-opioid controlled substances and is expected to be earnings accretive while creating long-term value through synergies, pipeline expansion, and combined strengths with the Lannett team.
About the Company
Aurobindo Pharma is a leading Indian multinational pharmaceutical company headquartered in Hyderabad, India, that manufactures generic drugs, branded specialty drugs, and active pharmaceutical ingredients (APIs). It is globally recognized as one of the largest generic pharmaceutical companies by prescriptions dispensed in the United States.
Financial Highlight: The revenue from operations grew by 6 percent to Rs 8,853 crore in Q4 FY26 from Rs 8,382 crore in Q4 FY25, and EBIDT decreased by 1 percent to Rs 1,750 crore in Q4 FY26 from Rs 1,760 crore in Q4 FY25. This was accompanied by a net profit growth of 2 percent to Rs 921 crore in Q4 FY26 from Rs 903 crore in Q4 FY25, resulting in an EPS growth of 2 percent to Rs 15.86 per share in Q4 FY26 from Rs 15.56 per share in Q4 FY25.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
